Literature DB >> 18157146

Resveratrol is an effective inducer of CArG-driven TNF-alpha gene therapy.

K A Bickenbach1, J Veerapong, M Y Shao, H J Mauceri, M C Posner, S J Kron, R R Weichselbaum.   

Abstract

We report the anticarcinogenic, anti-aging polyphenol resveratrol activates the radio- and chemo-inducible cancer gene therapy vector Ad.Egr.TNF, a replication-deficient adenovirus that expresses human tumor necrosis factor alpha (TNF-alpha) under control of the Egr-1 promoter. Like ionizing radiation or chemotherapeutic agents previously shown to activate Ad.Egr.TNF, resveratrol also induces Egr-1 expression from its chromosomal locus with a possible role for Egr-1 promoter CC(A+T)richGG sequences in the expression of TNF-alpha. Resveratrol induction of TNF-alpha in Ad.Egr.TNF-infected tumor xenografts demonstrated antitumor response in human and rat tumor models comparable to that of radio- or chemotherapy-induced TNF-alpha. Although sirtuins are known targets of resveratrol, in vitro inhibition of SIRT1 activity did not abrogate resveratrol induction of Egr-1 expression. This suggests that SIRT1 is not essential to mediate resveratrol induction of Egr-1. Nevertheless, control of transgene expression via resveratrol activation of Egr-1 may extend use of Ad.Egr.TNF to patients intolerant of radiation or cytotoxic therapy and offer a novel tool for development of other inducible gene therapies.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18157146     DOI: 10.1038/sj.cgt.7701103

Source DB:  PubMed          Journal:  Cancer Gene Ther        ISSN: 0929-1903            Impact factor:   5.987


  13 in total

Review 1.  Limitations in anti-obesity drug development: the critical role of hunger-promoting neurons.

Authors:  Marcelo O Dietrich; Tamas L Horvath
Journal:  Nat Rev Drug Discov       Date:  2012-08-03       Impact factor: 84.694

Review 2.  Chapter seven--Cancer treatment with gene therapy and radiation therapy.

Authors:  Sergey A Kaliberov; Donald J Buchsbaum
Journal:  Adv Cancer Res       Date:  2012       Impact factor: 6.242

Review 3.  Friend or foe, the role of EGR-1 in cancer.

Authors:  Tong-Tong Li; Man-Ru Liu; Dong-Sheng Pei
Journal:  Med Oncol       Date:  2019-11-20       Impact factor: 3.064

4.  Resveratrol and siRNA in combination reduces Hsp27 expression and induces caspase-3 activity in human glioblastoma cells.

Authors:  Evren Önay Uçar; Aslıhan Şengelen
Journal:  Cell Stress Chaperones       Date:  2019-05-09       Impact factor: 3.667

5.  Resveratrol Delivery via Gene Therapy: Entering the Modern Era

Authors:  Gurinder Singh
Journal:  Turk J Pharm Sci       Date:  2022-02-28

Review 6.  Tumor necrosis factor and cancer, buddies or foes?

Authors:  Xia Wang; Yong Lin
Journal:  Acta Pharmacol Sin       Date:  2008-11       Impact factor: 6.150

Review 7.  Is EGR1 a potential target for prostate cancer therapy?

Authors:  Delphine Gitenay; Véronique T Baron
Journal:  Future Oncol       Date:  2009-09       Impact factor: 3.404

8.  An oncolytic adenovirus regulated by a radiation-inducible promoter selectively mediates hSulf-1 gene expression and mutually reinforces antitumor activity of I131-metuximab in hepatocellular carcinoma.

Authors:  Yan Zhang; Lin Fang; Quan'an Zhang; Qin Zheng; Jinlong Tong; Xiaohui Fu; Xiaoqing Jiang; Changqing Su; Junnian Zheng
Journal:  Mol Oncol       Date:  2012-11-07       Impact factor: 6.603

9.  Resveratrol inhibits Cdk5 activity through regulation of p35 expression.

Authors:  Elias Utreras; Anita Terse; Jason Keller; Michael J Iadarola; Ashok B Kulkarni
Journal:  Mol Pain       Date:  2011-07-07       Impact factor: 3.395

10.  Transcriptional control of Flt3 ligand targeted by fluorouracil-induced Egr-1 promoter in hematopoietic damage.

Authors:  Nan Du; Xuetao Pei; Jinming Zhou; Hui Zhao; Xiaosong Li; Yan Fu; Yixin Hao
Journal:  J Biomed Sci       Date:  2009-09-21       Impact factor: 8.410

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.